Posted by Michael Wonder on 20 Apr 2021
CureVac Swiss initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic
19 April 2021 - Review process started with submission of first CVnCoV data package.
CureVac Swiss today announced initiation of a rolling submission for CVnCoV, the company’s mRNA based COVID-19 vaccine candidate, for the use in Switzerland.
The application for authorisation was submitted to Swissmedic, the country’s authority responsible for the authorisation and supervision of therapeutic products including vaccines.
